Analgesics⏵
Antiandrogens⏵
Azvudine
Bromhexine
Budesonide
Colchicine
Conv. Plasma
Curcumin
Famotidine
Favipiravir
Fluvoxamine
Hydroxychlor..
Ivermectin
Lifestyle⏵
Melatonin
Metformin
Minerals⏵
Molnupiravir
Monoclonals⏵
Naso/orophar..⏵
Nigella Sativa
Nitazoxanide
Paxlovid
Quercetin
Remdesivir
Thermotherapy
Vitamins⏵
More⏵

Other
Feedback
Home
Top
Results
All ensovibep studies
Meta analysis
 
Feedback
Home
←
next
study
→
previous
study
c19early.org COVID-19 treatment researchEnsovibepEnsovibep (more..)
Melatonin Meta
Metformin Meta
Azvudine Meta
Bromhexine Meta Molnupiravir Meta
Budesonide Meta
Colchicine Meta
Conv. Plasma Meta Nigella Sativa Meta
Curcumin Meta Nitazoxanide Meta
Famotidine Meta Paxlovid Meta
Favipiravir Meta Quercetin Meta
Fluvoxamine Meta Remdesivir Meta
Hydroxychlor.. Meta Thermotherapy Meta
Ivermectin Meta
Home Adoption Other Treatments
@CovidAnalysis
All Studies   Meta Analysis    Recent:   
0 0.5 1 1.5 2+ Mortality 89% Improvement Relative Risk Hospitalization 87% Hospitalization/ER 78% Ensovibep  Novartis et al.  EARLY TREATMENT  RCT Is early treatment with ensovibep beneficial for COVID-19? RCT 400 patients in multiple countries (May - November 2021) Lower hospitalization (p=0.012) and fewer hosp./ER visits (p=0.017) c19early.org Novartis, Press Release, January 2022 Favors ensovibep Favors control

Novartis and Molecular Partners report positive topline data from Phase 2 study for ensovibep (MP0420), a DARPin antiviral therapeutic for COVID-19

Novartis, Press Release
Jan 2022  
  Post
  Facebook
Share
  Source   PDF   All   Meta
EMPATHY Part A RCT with 407 patients, 301 treated with ensovibep, showing statistically significant viral load reduction (details not provided), and lower mortality and hospitalization. For discussion see twitter.com.
Important missing comments or errors? Let us know.
risk of death, 89.0% lower, RR 0.11, p = 0.06, treatment 0 of 301 (0.0%), control 2 of 99 (2.0%), NNT 49, relative risk is not 0 because of continuity correction due to zero events (with reciprocal of the contrasting arm).
risk of hospitalization, 86.8% lower, RR 0.13, p = 0.01, treatment 2 of 301 (0.7%), control 5 of 99 (5.1%), NNT 23.
risk of hospitalization/ER, 78.1% lower, RR 0.22, p = 0.02, treatment 4 of 301 (1.3%), control 6 of 99 (6.1%), NNT 21.
Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates
Novartis et al., 10 Jan 2022, Randomized Controlled Trial, multiple countries, preprint, 1 author, study period 10 May, 2021 - 18 November, 2021.
This PaperEnsovibepAll
Loading..
Please send us corrections, updates, or comments. c19early involves the extraction of 100,000+ datapoints from thousands of papers. Community updates help ensure high accuracy. Treatments and other interventions are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop   
Submit    
Post
Share
@CovidAnalysis
FAQ
Public domain CC0 1.0